RxDoctor Payments DataLook up a doctor →

Diaa Mikhail, MD

Family Medicine · Baltimore, MDNPI 1558391227

Payments from drug & device makers

$14,849in general payments, 2019–2025

Across 893 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • GSK$1K
  • AbbVie$1K
  • Sanofi-aventis U.S. LLC$810
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$14,71299%
  • Education$1361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,849 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$185,481
Medicare patients
344
Services billed
2,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$240,042
EliquisApixaban94$120,925
JardianceEmpagliflozin85$93,174
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$91,699
Tresiba Flextouch U-200Insulin Degludec35$67,839
TrulicityDulaglutide30$50,607
FarxigaDapagliflozin Propanediol37$42,772
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$41,884
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$41,224
XareltoRivaroxaban27$24,135
MyrbetriqMirabegron32$24,004
MounjaroTirzepatide15$18,469
Combivent RespimatIpratropium/Albuterol Sulfate12$16,919
EntrestoSacubitril/Valsartan20$12,991
Soliqua 100-33Insulin Glargine/Lixisenatide13$12,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,576$240,042134 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$1,398$141,029190 claims
PfizerEliquis$733$120,92594 claims
Boehringer IngelheimJardiance, Combivent Respimat$462$110,09397 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,809$93,922109 claims
Lilly USA, LLCTrulicity, Mounjaro$1,713$69,07645 claims
Johnson & JohnsonXarelto$184$24,13527 claims
Astellas Pharma US IncMyrbetriq$311$24,00432 claims
NovartisEntresto$106$12,99120 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$810$12,93913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →